An efficient new formulation of fusidic acid and betamethasone 17-valerate (Fucicort® Lipid cream) for treatment of clinically infected atopic dermatitis

Acta Dermato-Venereologica

Volumn 87, Issue 1, 2007, Pages 62-68

  Schultz Larsen, Finn ^a   Simonsen, Lene ^b   Melgaard, Anita ^b   Wendicke, Katja ^b   Henriksen, Anne S ^b  

^a Dermatology Clinic   (Denmark)

^b LEO PHARMA A S   (Denmark)

Author keywords

Combination therapy; Infected eczema; Lipid formulation; Randomized controlled trial

Indexed keywords

BETAMETHASONE VALERATE; DRUG VEHICLE; FUCICORT; FUSIDIC ACID; HYDROCORTISONE; MILDISON; UNCLASSIFIED DRUG; WATER OIL CREAM;

ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; DRY SKIN; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURIGO; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN PAIN; SKIN TIGHTNESS; URTICARIA;

ADMINISTRATION, TOPICAL; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE 17-VALERATE; DERMATITIS, ATOPIC; FEMALE; FUSIDIC ACID; HUMANS; MALE; PROSPECTIVE STUDIES; SAFETY; SKIN DISEASES, INFECTIOUS; TREATMENT OUTCOME;

EID: 33846853102     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0174     Document Type: Article

References (28)

1. Schultz Larsen F, Hanifin JM. Epidemiology of atopic dermatitis. Immunol All Clin North America 2002; 22: 1-24.
2. Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003; 361: 151-160.
3. Abeck D, Mempel M. Staphylococcus aureus colonisation in atopic dermatitis and its therapeutic implications. Br J Dermatol 1998; 139: 13-16.
4. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974; 90: 525-530.
5. Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976; 95: 323-328.
6. Hjorth N, Schmidt H, Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica 1985; 4: 126-131.
7. Ramsay CA, Savoie JM, Gilbert M, Gidon M, Kidson P. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol 1996; 7 (suppl 1): 15-22.
8. Javier PR, Ortiz M, Torralba M, Montinola FL, Lim KE, Canete R. Fusidic acid/betamethasone in infected dermatoses - a double-blind comparison with neomycin/betamethasone. Br J Clin Prac 1986; 40: 235-238.
9. Strategos J. Fusidic acid-betamethasone combination in infected eczema: an open, randomized comparison with gentamicin-betamethasone combination. Pharmatherapeutica 1986; 4: 601-606.
10. Menday AP, Noble WC. Topical betamethasone/fusidic acid in eczema: efficacy against and emergence of resistance in Staphylococcus aureus. J Dermatol Treat 2000; 11: 143-149.
11. Wilkinson JD, Leigh DA, Menday AP. Comparative efficacy of betamethasone and either fusidic acid or neomycin in infected or potentially infected eczema. Curr Ther Res 1985; 38: 177-182.
12. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; suppl 92: 44-47.
13. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests; approved standard. Seventh edition. NCCLS document M02-A7. Wayne, PA, US, 2000.
14. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. Fifth edition. NCCLS document M07-A5. Wayne, PA, US, 2000.
15. Note for guidance on statistical principles for clinical trials. The European Agency for the Evaluation of Medicinal Products. CPMP/ICH/363/96. London, UK, 1998.
16. SAS Institute Inc., SAS OnlineDoc®, version 8, Cary, NC, USA. SAS Institute Inc., 1999.
17. Lacour M, Hauser C. The role of microorganisms in atopic dermatitis. Clin Rev Allergy 1993; 11: 491-522.
18. Leyden JJ, Kligman AM. The case for steroid-antibiotic combinations. Br J Dermatol 1977; 96: 179-187.
19. Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988; 119: 189-198.
20. Stalder JF, Fleury M, Sourisse M, Rostin M, Pheline F, Litoux P. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994; 131: 536-540.
21. Filius PM, Gyssens IC. Impact of increasing antimicrobial resistance on wound management. Am J Clin Dermatol 2002; 3: 1-7.
22. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: A guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22: 406-419.
23. Korting HC, Neubert U, Abeck D. Current antimicrobial susceptibility of cutaneous bacteria to first line antibiotics. Int J Antimicrob Agents 1998; 10: 165-168.
24. Osterlund A, Eden T, Olsson-Liljequist B, Haeggman S, Kahlmeter G. Clonal spread among Swedish children of Staphylococcus aureus resistant to fusidic acid. Scand J Inf Dis 2002; 34: 729-734.
25. Livermore D, James D, Duckworth G, Stephens P. Fusidic acid use and resistance. Lancet 2002; 360: 806.
26. Mason BW, Howard AJ, Magee JT. Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing. J Antimicrob Chemother 2003; 51: 1033-1036.
27. Ravenscroft JC, Layton AM, Eady EA, Murtagh MS, Coates P, Walker M, Cove JH. Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid (FusR) Staphylococcus aureus in atopic eczema. Br J Dermatol 2003; 148: 1010-1017.
28. Perera G, Hay R. A guide to antibiotic resistance in bacterial skin infections. J Eur Acad Dermatol Venereol. 2005; 19: 531-545.